Evaluation Of [I-131]I- And [Lu-177]Lu-Dtpa-A11 Minibody For Radioimmunotherapy In A Preclinical Model Of Psca-Expressing Prostate Cancer

Purpose Radioimmunotherapy uses tumor-specific antibodies to deliver therapeutic radionuclides, but hematological toxicity due to the long serum half-life of intact antibodies remains a challenge. We evaluated a smaller antibody fragment, the minibody, with faster kinetics and a potentially improved therapeutic index. Procedures The anti-prostate stem cell antigen (PSCA) minibody (A11 Mb) was radiolabeled with iodine-124 ([I-124]I-A11 Mb) or conjugated with deferoxamine (DFO) and labeled with zirconium-89 ([Zr-89]Zr-DFO-A11 Mb) for surrogate immunoPET to profile pharmacokinetics in a human prostate cancer xenograft model. Subsequently, minibodies labeled with two therapeutic beta emitters, directly iodinated [I-131]I-A11 Mb (non-residualizing) and(177)Lu chelated using DTPA ([Lu-177]Lu-DTPA-A11 Mb) (residualizing), were compared forin vitroantigen-specific cytotoxicity. Full biodistribution studies (in 22Rv1-PSCA tumor bearing and hPSCA knock-in mice) were conducted for dosimetry calculations. Finally, the lead candidate [I-131]I-A11 Mb was evaluated in a radioimmunotherapy experiment. Escalating single doses (3.7, 11, or 37 MBq) and saline control were administered to 22Rv1-PSCA tumor bearing mice and anti-tumor effects (tumor volume) and toxicity (body weight) were monitored. Results Minibodies radiolabeled with therapeutic beta emitters [I-131]I-A11 Mb and [Lu-177]Lu-DTPA-A11 Mb exhibited comparable tumor cell growth inhibitionin vitro.In vivosurrogate immunoPET imaging using [Zr-89]Zr-DFO-A11 Mb showed activity retention in liver and kidney up to 72 h, while [I-124]I-A11 Mb cleared from liver, kidney, and blood by 48 h. Based on full biodistribution and dosimetry calculations, administering 37 MBq [I-131]I-A11 Mb was predicted to deliver a favorable dose to the tumor (35 Gy), with a therapeutic index of 22 (tumor:bone marrow). For [Lu-177]Lu-DTPA-A11 Mb, the kidneys would be dose-limiting, and the maximum tolerated activity (7.4 MBq) was not predicted to deliver an effective radiation dose to tumor. Radioimmunotherapy with a single dose of [I-131]I-A11 Mb showed dose-dependent tumor inhibition with minimal off-target toxicity and improved median survival (19 and 24 days,P < 0.001) compared with untreated mice (12 days). Conclusions These findings show the potential of the anti-PSCA minibody for targeted radioimmunotherapy with minimal toxicity, and the application of immunoPET and dosimetry for personalized treatment.